Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC)

This study is investigating whether treating the sites of cancer recurrence with radiation or surgery (recurrence-directed therapy, or RDT) — with or without hormone therapy — is beneficial for men with prostate cancer that has returned after prior radiation therapy, when the cancer has spread to only a few spots (oligometastatic). **You may be eligible if...** - You have previously been treated with definitive radiation therapy for localized prostate cancer, at least 2 years ago - Your prostate cancer has come back and is now present in 5 or fewer metastatic sites on imaging (including advanced scans like PSMA-PET) - Your PSA level is rising but your testosterone is not yet at castrate levels - All sites of recurrence can potentially be treated with radiation or surgery **You may NOT be eligible if...** - You have more than 5 metastatic sites - Your prostate cancer is castration-resistant (no longer responding to hormone therapy) - Your recurrence sites cannot safely be targeted with local treatment Talk to your doctor to see if this trial is right for you.